全文获取类型
收费全文 | 2145篇 |
免费 | 161篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 62篇 |
妇产科学 | 51篇 |
基础医学 | 249篇 |
口腔科学 | 172篇 |
临床医学 | 177篇 |
内科学 | 446篇 |
皮肤病学 | 80篇 |
神经病学 | 139篇 |
特种医学 | 38篇 |
外科学 | 252篇 |
综合类 | 60篇 |
一般理论 | 4篇 |
预防医学 | 207篇 |
眼科学 | 130篇 |
药学 | 129篇 |
中国医学 | 12篇 |
肿瘤学 | 95篇 |
出版年
2023年 | 25篇 |
2022年 | 46篇 |
2021年 | 108篇 |
2020年 | 66篇 |
2019年 | 103篇 |
2018年 | 77篇 |
2017年 | 52篇 |
2016年 | 71篇 |
2015年 | 79篇 |
2014年 | 84篇 |
2013年 | 129篇 |
2012年 | 159篇 |
2011年 | 140篇 |
2010年 | 83篇 |
2009年 | 67篇 |
2008年 | 105篇 |
2007年 | 120篇 |
2006年 | 95篇 |
2005年 | 95篇 |
2004年 | 76篇 |
2003年 | 71篇 |
2002年 | 44篇 |
2001年 | 24篇 |
2000年 | 31篇 |
1999年 | 31篇 |
1998年 | 14篇 |
1997年 | 17篇 |
1995年 | 6篇 |
1992年 | 17篇 |
1991年 | 20篇 |
1990年 | 15篇 |
1989年 | 28篇 |
1988年 | 18篇 |
1987年 | 15篇 |
1986年 | 10篇 |
1985年 | 16篇 |
1984年 | 7篇 |
1983年 | 8篇 |
1981年 | 8篇 |
1979年 | 13篇 |
1977年 | 5篇 |
1975年 | 6篇 |
1974年 | 9篇 |
1973年 | 6篇 |
1972年 | 9篇 |
1971年 | 12篇 |
1969年 | 15篇 |
1968年 | 8篇 |
1967年 | 7篇 |
1966年 | 7篇 |
排序方式: 共有2315条查询结果,搜索用时 234 毫秒
101.
Farah Kaissar Leroy Henri-Arthur Karnoub Melodie-Anne Obled Louis Fuentes Stephane Assaker Richard 《European spine journal》2020,29(2):306-313
European Spine Journal - To evaluate whether left hip positioning widened the access corridor using oblique lateral interbody fusion (OLIF) approach during right lateral decubitus (RLD). Ten... 相似文献
102.
Farah Rahman Sean T. H. Liu Sarah Taimur Samantha Jacobs Timothy Sullivan Dallas Dunn Emily Baneman Risa Fuller Judith A. Aberg Nicole Bouvier Meenakshi M. Rana 《Clinical transplantation》2020,34(12):e14089
Solid organ transplant (SOT) recipients may be at higher risk for poor outcomes with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Convalescent plasma is an investigational therapy that may benefit immunosuppressed patients by providing passive immunity. Convalescent plasma was administered to hospitalized patients with coronavirus disease-2019 (COVID-19) at an academic transplant center in New York City. Eligible patients were hospitalized and required to have positive nasopharyngeal polymerase chain reaction (PCR) diagnosis of SARS-CoV-2 infection, be at least 18 years old, and have either dyspnea, blood oxygen saturation ≤ 93% on ambient air, respiratory frequency ≥ 30 breaths/min, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, or lung infiltrates > 50%. Thirteen SOT recipients received convalescent plasma from April 9, 2020, to May 17, 2020. The median time from symptom onset to plasma infusion was 8 days. Eight of 13 patients (62%) had de-escalating oxygenation support by day 7 post-convalescent plasma. Nine (69%) patients were discharged, 1 (7%) patients remain hospitalized, and 3 (23%) patients died. This series supports the need for additional studies on convalescent plasma use in SOT recipients with COVID-19 to better determine efficacy and identify patients who are likely to benefit. 相似文献
103.
Azam TOFIGHI NAEEM Shima MAHMOUDI Farah SABOUI Homa HAJJARAN Babak POURAKBARI Mehdi MOHEBALI Mohammad Reza ZARKESH Setareh MAMISHI 《Iranian Journal of Parasitology》2014,9(1):1-5
Background
Visceral leishmaniasis (VL) is one of the most important parasitic diseases endemic in northwestern and southern areas of Iran. The aim of the present study was to review the records of children hospitalized with VL in order to characterize the clinical features of children as well as laboratory finding in Children Medical Center Hospital, Tehran, Iran.Methods
The medical records of all children with a final diagnosis of VL were reviewed from 2004 to 2011. Demographic, clinical information, laboratory finding and treatment were considered.Results
A total number of 34 children with confirmed VL through 2004-2011 were included in the study. The most prevalent sign and symptoms were fever (97.1%), pallor and weakness (97.1%), appetite loss (61.8%), splenomegaly (97.1%) and hepatomegaly (88.2%). The most frequent laboratory abnormalities were hematological including anemia (97.1%), thrombocytopenia (91.2%) and leukopenia (67.6%). Direct agglutination test (DAT) was performed in 23 cases and all of them showed anti-Leishmania antibodies with titers of ≥ 1: 3200. In addition, 90% of patients had positive rK39 results. Identification of Leishmania in the aspirates of the bone marrow was found in 83.3% of patients.Conclusion
Regional surveillance system in order to monitoring of leishmaniasis trends as well as detection of new emerging foci is recommended. 相似文献104.
Dapsone is a drug commonly used in the treatment of various dermatological diseases. Here, we report the case of a 45-year-old female prescribed dapsone for chronic urticaria after which she developed extensive livedo reticularis in the limbs, abdomen, and trunk. The use of dapsone may be associated with a plethora of adverse effects including rash but livedo reticularis has been very rarely reported. Emphasis should be laid on the possible drug etiology in any patient who develops new signs and symptoms while on medications, even if it may not be supported by enough literature.KEY WORDS: Chronic urticaria, Dapsone, livedo reticularis, rash 相似文献
105.
Max L. Eckstein PhD Othmar Moser PhD Norbert J. Tripolt PhD Peter N. Pferschy MSc Anna A. M. Obermayer MD Harald Kojzar BSc Alexander Mueller MSc Farah Abbas BSc Caren Sourij MD Harald Sourij MD 《Diabetes, obesity & metabolism》2021,23(7):1681-1684
To investigate differences in heart rate variability (HRV) during oral glucose tolerance tests (OGTTs) in response to the rate of change in glucose and to different glycaemic ranges in individuals with type 1 diabetes. This was a single-centre, prospective, secondary outcome analysis in 17 individuals with type 1 diabetes (glycated haemoglobin 53 ± 6.3 mmol/L), who underwent two OGTTs (after 12 and 36 hours of fasting) investigating differences in HRV in response to rapid glucose increases/decreases and different glycaemic ranges during OGTT. Based on the rate of change in glucose level, the variables heart rate (P < 0.001), square root of the mean standard difference of successive R-R intervals (P = 0.002), percentage of pairs of R-R intervals with >50 ms difference (P < 0.001) and corrected QT interval (P = 0.04) were significantly altered, with HRV particularly reduced during episodes of rapid glucose rises. Glycaemic ranges during OGTT had no impact on HRV (P < 0.05). Individuals with type 1 diabetes showed no changes in HRV in response to different glycaemic ranges. HRV was dependent on the rate of change in glucose, especially rapid increases in glucose level. 相似文献
106.
Dushyant Singh Dahiya Asim Kichloo Jagmeet Singh Michael Albosta Farah Wani 《World journal of gastrointestinal endoscopy》2021,13(1):1
Amyloidosis, a heterogenous group of disorders, is characterized by the extracellular deposition of autologous, insoluble, fibrillar misfolded proteins. These extracellular proteins deposit in tissues aggregated in ß-pleated sheets arranged in an antiparallel fashion and cause distortion to the tissue architecture and function. In the current literature, about 60 heterogeneous amyloidogenic proteins have been identified, out of which 27 have been associated with human disease. Classified as a rare disease, amyloidosis is known to have a wide range of possible etiologies and clinical manifestations. The exact incidence and prevalence of the disease is currently unknown. In both systemic and localized amyloidosis, there is infiltration of the abnormal proteins in the layers of the gastrointestinal (GI) tract or the liver parenchyma. The gold standard test for establishing a diagnosis is tissue biopsy followed by Congo Red staining and apple-green birefringence of the Congo Red-stained deposits under polarized light. However, not all patients may have a positive tissue confirmation of the disease. In these cases additional workup and referral to a gastroenterologist may be warranted. Along with symptomatic management, the treatment for GI amyloidosis consists of observation or localized surgical excision in patients with localized disease, and treatment of the underlying pathology in cases of systemic amyloidosis. In this review of the literature, we describe the subtypes of amyloidosis, with a primary focus on the epidemiology, pathogenesis, clinical features, diagnosis and treatment strategies available for GI amyloidosis. 相似文献
107.
108.
Aharonian VJ Farah MG 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》1983,10(1):17-21
The echocardiographic features in seven patients with flail aortic leaflets are described and are correlated with the anatomical appearance of the valve at the time of surgery or autopsy. M-mode echocardiography showed coarse and "shaggy" diastolic echoes within the aortic root and thickening of the aortic leaflets during systole in all patients. Six patients had coarse and "shaggy" diastolic echoes within the left ventricular outflow tract in continuity with similar echoes within the aortic root. Cross-sectional echocardiography in three patients revealed a cord-like mass prolapsing into the left ventricular outflow tract during diastole. Three of the patients had no vegetations at the time of surgery. Both modes of echocardiography are of value in demonstrating abnormal echoes prolapsing into the left ventricular outflow tract, characteristic of flail aortic leaflets that can occur in the presence or absence of vegetations. 相似文献
109.
Carlos G. Santos-Gallego Ariana P. Vargas-Delgado Juan Antonio Requena-Ibanez Alvaro Garcia-Ropero Donna Mancini Sean Pinney Frank Macaluso Samantha Sartori Merce Roque Fernando Sabatel-Perez Anderly Rodriguez-Cordero M. Urooj Zafar Icilma Fergus Farah Atallah-Lajam Johanna P. Contreras Cathleen Varley Pedro R. Moreno Vivian M. Abascal Juan J. Badimon 《Journal of the American College of Cardiology》2021,77(3):243-255
BackgroundLarge clinical trials established the benefits of sodium-glucose cotransporter 2 inhibitors in patients with diabetes and with heart failure with reduced ejection fraction (HFrEF). The early and significant improvement in clinical outcomes is likely explained by effects beyond a reduction in hyperglycemia.ObjectivesThe purpose of this study was to assess the effect of empagliflozin on left ventricular (LV) function and volumes, functional capacity, and quality of life (QoL) in nondiabetic HFrEF patients.MethodsIn this double-blind, placebo-controlled trial, nondiabetic HFrEF patients (n = 84) were randomized to empagliflozin 10 mg daily or placebo for 6 months. The primary endpoint was change in LV end-diastolic and -systolic volume assessed by cardiac magnetic resonance. Secondary endpoints included changes in LV mass, LV ejection fraction, peak oxygen consumption in the cardiopulmonary exercise test, 6-min walk test, and quality of life.ResultsEmpagliflozin was associated with a significant reduction of LV end-diastolic volume (?25.1 ± 26.0 ml vs. ?1.5 ± 25.4 ml for empagliflozin vs. placebo, respectively; p < 0.001) and LV end-systolic volume (?26.6 ± 20.5 ml vs. ?0.5 ± 21.9 ml for empagliflozin vs. placebo; p < 0.001). Empagliflozin was associated with reductions in LV mass (?17.8 ± 31.9 g vs. 4.1 ± 13.4 g, for empagliflozin vs. placebo, respectively; p < 0.001) and LV sphericity, and improvements in LV ejection fraction (6.0 ± 4.2 vs. ?0.1 ± 3.9; p < 0.001). Patients who received empagliflozin had significant improvements in peak O2 consumption (1.1 ± 2.6 ml/min/kg vs. ?0.5 ± 1.9 ml/min/kg for empagliflozin vs. placebo, respectively; p = 0.017), oxygen uptake efficiency slope (111 ± 267 vs. ?145 ± 318; p < 0.001), as well as in 6-min walk test (81 ± 64 m vs. ?35 ± 68 m; p < 0.001) and quality of life (Kansas City Cardiomyopathy Questionnaire-12: 21 ± 18 vs. 2 ± 15; p < 0.001).ConclusionsEmpagliflozin administration to nondiabetic HFrEF patients significantly improves LV volumes, LV mass, LV systolic function, functional capacity, and quality of life when compared with placebo. Our observations strongly support a role for sodium-glucose cotransporter 2 inhibitors in the treatment of HFrEF patients independently of their glycemic status. (Are the “Cardiac Benefits” of Empagliflozin Independent of Its Hypoglycemic Activity? [ATRU-4] [EMPA-TROPISM]; NCT03485222) 相似文献
110.
Marcelo F Vela Joel E Richter Farah Khandwala Eugene H Blackstone Don Wachsberger Mark E Baker Thomas W Rice 《Clinical gastroenterology and hepatology》2006,4(5):580-587
BACKGROUND & AIMS: Studies comparing long-term success after pneumatic dilatation (PD) and laparoscopic Heller myotomy (HM) are lacking. This study compares long-term outcome of PD (single dilatation and graded approach) and laparoscopic HM and identifies risk factors for treatment failure. METHODS: A cross-sectional follow-up evaluation of an achalasia cohort treated between 1994 and 2002 was followed-up for a mean of 3.1 years. There was a total of 106 patients treated by graded PD (1-3 dilatations with progressively larger balloons) and 73 patients treated by HM (20 had failed graded PD and crossed over to HM). A symptom assessment (structured telephone interview or clinic visit) was performed and patients were given freedom from alternative therapies to determine treatment outcome. Endoscopy, manometry, and timed barium esophagram were performed to determine the cause of treatment failure. RESULTS: The success of single PD was defined as freedom from additional PDs: 62% at 6 months and 28% at 6 years (risk factors for failure: younger age, male sex, wider esophagus, and poor emptying on posttreatment timed barium esophagram). Freedom from subsequent PDs increased with each dilatation (graded PD). The success of graded PD and HM, defined as dysphagia/regurgitation less than 3 times/wk or freedom from alternative treatment, was similar: 90% vs 89% at 6 months and 44% vs 57% at 6 years (no risk factors for failure were identified). Causes of symptom recurrence were incompletely treated achalasia (96% after PD vs 64% after HM) and gastroesophageal reflux disease (4% after PD vs 36% after HM). CONCLUSIONS: No treatment cures achalasia. Short- and long-term success is similar for graded PD and laparoscopic HM. Therapeutic success decreases steadily over time. Achalasia patients need careful long-term follow-up evaluation. 相似文献